Disease

NIPD for Apert syndrome

Contact details
Regional Genetics Service
Level 5/6, Barclay House
37 Queen Square
London, WC1N 3BH
T +44 (0) 20 7762 6888
F +44 (0) 20 7813 8578

Samples required

- **Pregnant Women**
  2x 10mls venous blood in plastic EDTA bottles or glass Streck tubes, this should ideally reach the laboratory within 24-48 hours of sampling
- The minimum gestation (by scan) is 9wks for accepting a sample. If earlier than 18wks then 2 blood samples a week apart may be required
- **Testing must be arranged in advance**, through your Local Clinical Genetics Department or Fetal Medicine Unit
- A completed DNA request card and ultrasound report should accompany all samples with an appropriate telephone number and a secure fax number.
- **Pregnancy outcome**
  Details of pregnancy outcome will be required for confirmation of laboratory results as part of the ongoing validation of new tests

Patient details
To facilitate accurate testing and reporting please provide patient demographic details (full name, date of birth, address), details of any relevant family history and full contact details for the referring clinician

Introduction

Apert syndrome (MIM 101200) is a congenital disorder characterised primarily by craniosynostosis, midface hypoplasia, and syndactyly of the hands and feet with a tendency to fusion of bony structures. Most cases are sporadic, but autosomal dominant inheritance has been reported. Apert syndrome can be very severe and is easily distinguishable from other craniosynostosis syndromes. Two mutations in FGFR2 exon 8, c.755C>G p.(Ser252Trp) and c.758C>G p.(Pro253Arg), account for over 98% of reported cases.

Non-invasive prenatal genetic diagnosis (NIPD) is now possible using cell free fetal DNA (cffDNA) in pregnancies at risk of Apert syndrome.

Referrals

All referrals should be made via a Clinical Genetics Department or Fetal Medicine Unit and will be accepted in either of the categories given below. If you wish to refer a case which does not fulfil these criteria please contact Professor Lyn Chitty (l.chitty@ucl.ac.uk) (Clinical) or the laboratory (Genetics.Labs@gosh.nhs.uk)

1. At risk pregnancy
   - Paternal Apert syndrome OR
   - a previous pregnancy has been confirmed to have Apert syndrome, thus there is a very small risk of recurrence due to germline mosaicism
2. Abnormal ultrasound findings
   - Acrocephaly AND
   - Symmetrical syndactyly

Service offered

Targeted next generation sequencing (NGS) for c.755C>G p.(Ser252Trp), c.758C>G p.(Pro253Arg) and c.755_756delinsTT p.(Ser252Phe) mutations in FGFR2.

Technical

Maternal EDTA blood is spun as soon as possible after collection, cffDNA is extracted from plasma. Molecular analysis is performed by PCR, followed by NGS (Illumina MiSeq). Amplification of fetal DNA will be confirmed using HLA markers, or ZFY-specific sequences.

Target reporting time

Results are normally available within 5 days of sample receipt.